The HLCS Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the SK-HEP-1 human hepatocellular carcinoma line, engineered to disrupt the HLCS gene. This knockout model provides a powerful tool for investigating the loss of holocarboxylase synthetase activity, which catalyzes biotinylation of apocarboxylases and histones. The polyclonal nature of this product ensures genetic heterogeneity, reflecting a range of editing events across the population without clonal selection, making it suitable for pooled functional studies where diverse mutations are beneficial.
The SK-HEP-1 cell line, originally established from the ascites of a patient with liver adenocarcinoma, exhibits epithelial morphology and retains key metabolic features of hepatic cancer cells. Widely employed in liver cancer research, these cells support investigations into tumor metabolism, proliferation, and drug response. Their origin from ascites fluid also provides a relevant context for studying metastatic behavior and the metabolic adaptations of cancer cells in nutrient-limited environments.
HLCS functions as a pivotal enzyme in biotin metabolism, catalyzing the ATP-dependent covalent attachment of biotin to critical carboxylases??including acetyl-CoA carboxylase (ACACA), pyruvate carboxylase (PC), propionyl-CoA carboxylase (PCCA), and 3-methylcrotonyl-CoA carboxylase (MCCC1)??as well as to histones H3 and H4. This activity is regulated upstream by factors such as biotin availability, the biotin transporter SLC5A6, and insulin signaling. By biotinylating histones, HLCS also influences chromatin structure and gene expression, linking nutrient status to epigenetic regulation. Disruption of HLCS abrogates these events, leading to deficient carboxylase function and altered transcriptional programs.
In SK-HEP-1 cells, HLCS knockout offers a physiologically relevant model to examine how biotin-dependent metabolic pathways intersect with hepatocellular carcinoma biology. The loss of HLCS in a liver-derived cancer line allows dissection of its roles in fatty acid synthesis, gluconeogenesis, and branched-chain amino acid catabolism??processes that are frequently reprogrammed in cancer. This model also enables investigation of histone biotinylation in the context of liver cancer epigenetics and can be used to mimic aspects of holocarboxylase synthetase deficiency or multiple carboxylase deficiency in a hepatic cellular environment.
Typical applications include metabolic flux analyses to track biotin-dependent carboxylase activity, western blotting for global biotinylated proteins, RT-qPCR to quantify carboxylase expression, and ChIP-qPCR to assess histone biotinylation marks. The polyclonal knockout population is particularly suited for drug screening assays targeting biotin-related pathways, proliferation studies, and mechanistic dissection of biotin-mediated gene regulation in cancer metabolism. For further inquiries, please contact Ascent Research.
